INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 155 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,426,663 | +123.7% | 101,495 | +84.9% | 0.23% | +48.1% |
| Q4 2021 | $2,873,000 | +212.6% | 54,885 | +122.7% | 0.16% | +243.5% |
| Q3 2021 | $919,000 | -66.0% | 24,642 | -62.8% | 0.05% | -56.2% |
| Q2 2021 | $2,704,000 | -38.7% | 66,232 | -49.1% | 0.10% | -26.1% |
| Q1 2021 | $4,412,000 | -29.3% | 130,032 | -33.7% | 0.14% | -55.2% |
| Q4 2020 | $6,237,000 | +116.0% | 196,126 | +74.3% | 0.32% | +77.1% |
| Q2 2020 | $2,888,000 | +456.5% | 112,500 | +181.2% | 0.18% | +397.2% |
| Q2 2019 | $519,000 | -59.0% | 40,000 | -61.5% | 0.04% | -49.3% |
| Q1 2019 | $1,267,000 | -79.7% | 104,000 | -75.9% | 0.07% | -78.4% |
| Q4 2017 | $6,253,000 | +42.3% | 431,874 | +55.1% | 0.33% | +48.4% |
| Q3 2017 | $4,393,000 | +320.0% | 278,400 | +230.6% | 0.22% | +287.7% |
| Q2 2017 | $1,046,000 | +37.3% | 84,200 | +68.4% | 0.06% | +29.5% |
| Q3 2016 | $762,000 | – | 50,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |